Overview

  • Product name

    Anti-CBL (phospho Y700) antibody
    See all CBL primary antibodies
  • Description

    Rabbit polyclonal to CBL (phospho Y700)
  • Host species

    Rabbit
  • Tested applications

    Suitable for: WB, IHC-P, ICC/IFmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat
  • Immunogen

    Synthetic peptide conjugated to KLH, surrounding the phosphorylation site of tyrosine 700 (

    T-E-Y(p)-M-T

    ) of Human CBL (NP_005179.2).

  • Positive control

    • HeLa cells; HT29 cell extracts, treated with UV; Human breast carcinoma tissue.

Properties

Applications

Our Abpromise guarantee covers the use of ab131345 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/500 - 1/1000. Detects a band of approximately 120 kDa (predicted molecular weight: 100 kDa). Incubate membrane with diluted antibody in 5% nonfat milk, 1X TBS and 0.1% Tween 20, at 4C, with gentle shaking, overnight.
IHC-P 1/50 - 1/100.
ICC/IF 1/100 - 1/200.

Target

  • Function

    Participates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
  • Pathway

    Protein modification; protein ubiquitination.
  • Involvement in disease

    Defects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
  • Sequence similarities

    Contains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
    Contains 1 RING-type zinc finger.
    Contains 1 UBA domain.
  • Domain

    The RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
    The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
  • Post-translational
    modifications

    Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
  • Cellular localization

    Cytoplasm.
  • Information by UniProt
  • Database links

  • Alternative names

    • 4732447J05Rik antibody
    • C CBL antibody
    • Cas Br M (murine) ecotropic retroviral transforming sequence antibody
    • Casitas B lineage lymphoma proto oncogene antibody
    • Casitas B-lineage lymphoma proto-oncogene antibody
    • CBL 2 antibody
    • cbl antibody
    • CBL_HUMAN antibody
    • CBL2 antibody
    • E3 ubiquitin protein ligase CBL antibody
    • E3 ubiquitin-protein ligase CBL antibody
    • Oncogene CBL2 antibody
    • Proto oncogene c CBL antibody
    • Proto-oncogene c-CBL antibody
    • RGD1561386 antibody
    • RING finger protein 55 antibody
    • RNF55 antibody
    • Signal transduction protein CBL antibody
    see all

Images

  • All lanes : Anti-CBL (phospho Y700) antibody (ab131345) at 1/500 dilution

    Lane 1 : HT29 cell extracts
    Lane 2 : HT29 cell extracts treated with UV

    Predicted band size: 100 kDa

  • Immunofluorescent analysis of methanol-fixed HeLa cells labelling CBL with ab131345 at 1/100 dilution.
  • Immunohistochemical analysis of paraffin-embedded Human breast carcinoma tissue labelling CBL with ab131345 at 1/50 dilution, in the absence (left) and presence (right) of the blocking peptide.

References

ab131345 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab131345.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"
For licensing inquiries, please contact partnerships@abcam.com

Sign up